Skip to main content
×
Home

Bromodomains as therapeutic targets

  • Susanne Muller (a1), Panagis Filippakopoulos (a1) and Stefan Knapp (a1)
Abstract

Acetylation of lysine residues is a post-translational modification with broad relevance to cellular signalling and disease biology. Enzymes that ‘write’ (histone acetyltransferases, HATs) and ‘erase’ (histone deacetylases, HDACs) acetylation sites are an area of extensive research in current drug development, but very few potent inhibitors that modulate the ‘reading process’ mediated by acetyl lysines have been described. The principal readers of ɛ-N-acetyl lysine (Kac) marks are bromodomains (BRDs), which are a diverse family of evolutionary conserved protein-interaction modules. The conserved BRD fold contains a deep, largely hydrophobic acetyl lysine binding site, which represents an attractive pocket for the development of small, pharmaceutically active molecules. Proteins that contain BRDs have been implicated in the development of a large variety of diseases. Recently, two highly potent and selective inhibitors that target BRDs of the BET (bromodomains and extra-terminal) family provided compelling data supporting targeting of these BRDs in inflammation and in an aggressive type of squamous cell carcinoma. It is likely that BRDs will emerge alongside HATs and HDACs as interesting targets for drug development for the large number of diseases that are caused by aberrant acetylation of lysine residues.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Bromodomains as therapeutic targets
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Bromodomains as therapeutic targets
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Bromodomains as therapeutic targets
      Available formats
      ×
Copyright
Re-use permitted under a Creative Commons Licence–by-nc-sa
Corresponding author
*Corresponding author: Stefan Knapp, Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7LD, UK. E-mail: stefan.knapp@sgc.ox.ac.uk
References
Hide All
1Kouzarides T. (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO Journal 19, 1176-1179
2Choudhary C. et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840
3Shogren-Knaak M. et al. (2006) Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311, 844-847
4Kouzarides T. (2007) Chromatin modifications and their function. Cell 128, 693-705
5Guan K.L. and Xiong Y. (2011) Regulation of intermediary metabolism by protein acetylation. Trends in Biochemical Sciences 36, 108-116
6Celic I. et al. (2006) The sirtuins hst3 and Hst4p preserve genome integrity by controlling histone h3 lysine 56 deacetylation. Current Biology 16, 1280-1289
7Bertrand P. (2010) Inside HDAC with HDAC inhibitors. European Journal of Medicinal Chemistry 45, 2095-2116
8Bowers E.M. et al. (2010) Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chemistry and Biology 17, 471-482
9Mujtaba S., Zeng L. and Zhou M.M. (2007) Structure and acetyl-lysine recognition of the bromodomain. Oncogene 26, 5521-5527
10Vollmuth F. and Geyer M. (2010) Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains. Angewandte Chemie International Edition in English 49, 6768-6772
11Tamkun J.W. et al. (1992) brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 68, 561-572
12Haynes S.R. et al. (1992) The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins. Nucleic Acids Research 20, 2603
13Nagy Z. and Tora L. (2007) Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 26, 5341-5357
14Trotter K.W. and Archer T.K. (2008) The BRG1 transcriptional coregulator. Nuclear Receptor Signaling 6, 004
15Malik S. and Bhaumik S.R. (2010) Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human. FEBS Journal 277, 1805-1821
16Gregory G.D. et al. (2007) Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. Molecular and Cellular Biology 27, 8466-8479
17Bres V., Yoh S.M. and Jones K.A. (2008) The multi-tasking P-TEFb complex. Current Opinion in Cell Biology 20, 334-340
18Venturini L. et al. (1999) TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene 18, 1209-1217
19Jacobson R.H. et al. (2000) Structure and function of a human TAF(II)250 double bromodomain module. Science 288, 1422-1425
20Nakamura T. et al. (2000) huASH1 protein, a putative transcription factor encoded by a human homologue of the Drosophila ash1 gene, localizes to both nuclei and cell-cell tight junctions. Proceedings of the National Academy of Sciences of the United States of America 97, 7284-7289
21Mohan M. et al. (2010) Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nature Reviews. Cancer 10, 721-728
22Yu B.D. et al. (1995) Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378, 505-508
23Yagi H. et al. (1998) Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood 92, 108-117
24McMahon K.A. et al. (2007) Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 1, 338-345
25Radhakrishnan I. et al. (1997) Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator:coactivator interactions. Cell 91, 741-752
26Kalkhoven E. (2004) CBP and p300: HATs for different occasions. Biochemical Pharmacology 68, 1145-1155
27Tanaka Y. et al. (2000) Extensive brain hemorrhage and embryonic lethality in a mouse null mutant of CREB-binding protein. Mechanisms of Development 95, 133-145
28Yao T.P. et al. (1998) Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93, 361-372
29Bu P. et al. (2007) Loss of Gcn5 acetyltransferase activity leads to neural tube closure defects and exencephaly in mouse embryos. Molecular and Cellular Biology 27, 3405-3416
30Xu W. et al. (2000) Loss of Gcn5l2 leads to increased apoptosis and mesodermal defects during mouse development. Nature Genetics 26, 229-232
31Maurice T. et al. (2008) Altered memory capacities and response to stress in p300/CBP-associated factor (PCAF) histone acetylase knockout mice. Neuropsychopharmacology 33, 1584-1602
32Revenko A.S. et al. (2010) Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Molecular and Cellular Biology 30, 5260-5272
33Ciro M. et al. (2009) ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Research 69, 8491-8498
34Zou J.X. et al. (2007) ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proceedings of the National Academy of Sciences of the United States of America 104, 18067-18072
35Dey A. et al. (2000) A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition. Molecular and Cellular Biology 20, 6537-6549
36Kanno T. et al. (2004) Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Molecular Cell 13, 33-43
37Dey A. et al. (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proceedings of the National Academy of Sciences of the United States of America 100, 8758-8763
38Dey A. et al. (2000) A bromodomain protein, MCAP, associates with mitotic chromosomes and effects, G(2)–to-M transition. Molecular and Cellular Biology 20, 6537-6549
39Maruyama T. et al. (2002) A mammalian bromodomain protein, Brd4, interacts with replication factor C and inhibits progression to S phase. Molecular and Cellular Biology 22, 6509-6520
40Wu S.Y. et al. (2006) Brd4 links chromatin targeting to HPV transcriptional silencing. Genes and Development 20, 2383-2396
41Denis G.V. et al. (2006) Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. Journal of Proteome Research 5, 502-511
42Leroy G., Rickards B. and Flint S.J. (2008) The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Molecular Cell 30, 51-60
43Houzelstein D. et al. (2002) Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. Molecular and Cellular Biology 22, 3794-3802
44Shang E. et al. (2009) Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse. Developmental Dynamics 238, 908-917
45Gyuris A. et al. (2009) The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis. Biochimica Biophysica et Acta 1789, 413-421
46Wang F. et al. (2010) Brd2 disruption in mice causes severe obesity without Type 2 diabetes. Biochemical Journal 425, 71-83
47Shang E. et al. (2007) The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation. Development 134, 3507-3515
48Steilmann C. et al. (2010) The interaction of modified histones with the bromodomain testis-specific (BRDT) gene and its mRNA level in sperm of fertile donors and subfertile men. Reproduction 140, 435-443
49Aston K.I. et al. (2010) Evaluation of 172 candidate polymorphisms for association with oligozoospermia or azoospermia in a large cohort of men of European descent. Human Reproduction 25, 1383-1397
50Wassarman D.A. and Sauer F. (2001) TAF(II)250: a transcription toolbox. Journal of Cell Science 114, 2895-2902
51Deato M.D. and Tjian R. (2007) Switching of the core transcription machinery during myogenesis. Genes and Development 21, 2137-2149
52Buchmann A.M., Skaar J.R. and DeCaprio J.A. (2004) Activation of a DNA damage checkpoint response in a TAF1-defective cell line. Molecular and Cellular Biology 24, 5332-5339
53Lin C.Y. et al. (2002) The cell cycle regulatory factor TAF1 stimulates ribosomal DNA transcription by binding to the activator UBF. Current Biology 12, 2142-2146
54Kimura J. et al. (2008) A functional genome-wide RNAi screen identifies TAF1 as a regulator for apoptosis in response to genotoxic stress. Nucleic Acids Research 36, 5250-5259
55Jacobson R.H. et al. (2000) Structure and function of a human TAFII250 double bromodomain module. Science 288, 1422-1425
56Li A.G. et al. (2007) An acetylation switch in p53 mediates holo-TFIID recruitment. Molecular Cell 28, 408-421
57Wang P.J. and Page D.C. (2002) Functional substitution for TAF(II)250 by a retroposed homolog that is expressed in human spermatogenesis. Human Molecular Genetics 11, 2341-2346
58Kalla C. et al. (2005) Translocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes. Genes, Chromosomes and Cancer 42, 128-143
59Ramos V.C. et al. (2002) Characterisation and expression analysis of the WDR9 gene, located in the Down critical region-2 of the human chromosome 21. Biochimica Biophysica et Acta 1577, 377-383
60Philipps D.L. et al. (2008) The dual bromodomain and WD repeat-containing mouse protein BRWD1 is required for normal spermiogenesis and the oocyte-embryo transition. Developmental Biology 317, 72-82
61Huang H. et al. (2003) Expression of the Wdr9 gene and protein products during mouse development. Developmental Dynamics 227, 608-614
62Muller P. et al. (2005) Identification of JAK/STAT signalling components by genome-wide RNA interference. Nature 436, 871-875
63Borden K.L. (2000) RING domains: master builders of molecular scaffolds? Journal of Molecular Biology 295, 1103-1112
64Meroni G. and Diez-Roux G. (2005) TRIM/RBCC, a novel class of ‘single protein RING finger’ E3 ubiquitin ligases. Bioessays 27, 1147-1157
65Peng H., Feldman I. and Rauscher F.J. 3rd (2002) Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing nuclear cofactors: a potential mechanism for regulating the switch between coactivation and corepression. Journal of Molecular Biology 320, 629-644
66Remboutsika E. et al. (1999) The putative nuclear receptor mediator TIF1alpha is tightly associated with euchromatin. Journal of Cell Science 112 (Pt 11),1671-1683
67Le Douarin B. et al. (1996) A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO Journal 15, 6701-6715
68Friedman J.R. et al. (1996) KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes and Development 10, 2067-2078
69Cammas F. et al. (2002) Cell differentiation induces TIF1beta association with centromeric heterochromatin via an HP1 interaction. Journal of Cell Science 115, 3439-3448
70Li Y., Kirschmann D.A. and Wallrath L.L. (2002) Does heterochromatin protein 1 always follow code? Proceedings of the National Academy of Sciences of the United States of America 99 (Suppl 4),16462-16469
71Bartova E. et al. (2007) Differentiation-specific association of HP1alpha and HP1beta with chromocentres is correlated with clustering of TIF1beta at these sites. Histochemistry and Cell Biology 127, 375-388
72Cammas F. et al. (2004) Association of the transcriptional corepressor TIF1beta with heterochromatin protein 1 (HP1): an essential role for progression through differentiation. Genes and Development 18, 2147-2160
73Ivanov A.V. et al. (2007) PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. Molecular Cell 28, 823-837
74Zeng L. et al. (2008) Structural insights into human KAP1 PHD finger-bromodomain and its role in gene silencing. Nature Structural and Molecular Biology 15, 626-633
75Dupont S. et al. (2005) Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 121, 87-99
76He W. et al. (2006) Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 125, 929-941
77Kim J. and Kaartinen V. (2008) Generation of mice with a conditional allele for Trim33. Genesis 46, 329-333
78Khetchoumian K. et al. (2004) TIF1delta, a novel HP1-interacting member of the transcriptional intermediary factor 1 (TIF1) family expressed by elongating spermatids. Journal of Biological Chemistry 279, 48329-48341
79Bernardi R. and Pandolfi P.P. (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Reviews. Molecular Cell Biology 8, 1006-1016
80Boisvert F.M. et al. (2001) The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body. Journal of Cell Biology 152, 1099-1106
81Dellaire G. et al. (2006) Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. Journal of Cell Biology 175, 55-66
82Zhong S. et al. (1999) A role for PML and the nuclear body in genomic stability. Oncogene 18, 7941-7947
83Boisvert F.M., Hendzel M.J. and Bazett-Jones D.P. (2000) Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. Journal of Cell Biology 148, 283-292
84Wang J. et al. (2004) Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions. Journal of Cell Biology 164, 515-526
85Wu W.S. et al. (2001) The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Molecular and Cellular Biology 21, 2259-2268
86Stinton L.M. et al. (2011) Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clinical and Experimental Immunology 163, 147-156
87Ishov A.M. and Maul G.G. (1996) The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition. Journal of Cell Biology 134, 815-826
88Neigeborn L. and Carlson M. (1984) Genes affecting the regulation of SUC2 gene expression by glucose repression in Saccharomyces cerevisiae. Genetics 108, 845-858
89Stern M., Jensen R. and Herskowitz I. (1984) Five SWI genes are required for expression of the HO gene in yeast. Journal of Molecular Biology 178, 853-868
90Winston F. and Carlson M. (1992) Yeast SNF/SWI transcriptional activators and the SPT/SIN chromatin connection. Trends in Genetics 8, 387-391
91Sudarsanam P. et al. (2000) Whole-genome expression analysis of snf/swi mutants of Saccharomyces cerevisiae. Proceedings of the National Academy of Sciences of the United States of America 97, 3364-3369
92Ho L. et al. (2009) An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network. Proceedings of the National Academy of Sciences of the United States of America 106, 5187-5191
93Singhal N. et al. (2010) Chromatin-remodeling components of the BAF complex facilitate reprogramming. Cell 141, 943-955
94Peterson C.L., Dingwall A. and Scott M.P. (1994) Five SWI/SNF gene products are components of a large multisubunit complex required for transcriptional enhancement. Proceedings of the National Academy of Sciences of the United States of America 91, 2905-2908
95Shen W. et al. (2007) Solution structure of human Brg1 bromodomain and its specific binding to acetylated histone tails. Biochemistry 46, 2100-2110
96Link K.A. et al. (2005) BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Molecular and Cellular Biology 25, 2200-2215
97Aoyagi S., Trotter K.W. and Archer T.K. (2005) ATP-dependent chromatin remodeling complexes and their role in nuclear receptor-dependent transcription in vivo. Vitamins and Hormones 70, 281-307
98Debril M.B. et al. (2004) Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunit. Journal of Biological Chemistry 279, 16677-16686
99Trotter K.W. and Archer T.K. (2007) Nuclear receptors and chromatin remodeling machinery. Molecular and Cellular Endocrinology 162-167, 265-266
100Pal S. et al. (2003) mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad. Molecular and Cellular Biology 23, 7475-7487
101Zhang H.S. et al. (2000) Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 101, 79-89
102Subtil-Rodriguez A. and Reyes J.C. (2010) BRG1 helps RNA polymerase II to overcome a nucleosomal barrier during elongation, in vivo. EMBO Reports 11, 751-757
103Lemon B. et al. (2001) Selectivity of chromatin-remodelling cofactors for ligand-activated transcription. Nature 414, 924-928
104Ryme J. et al. (2009) Variations in the composition of mammalian SWI/SNF chromatin remodelling complexes. Journal of Cellular Biochemistry 108, 565-576
105Wang Z. et al. (2004) Polybromo protein BAF180 functions in mammalian cardiac chamber maturation. Genes and Development 18, 3106-3116
106Huang X. et al. (2008) Coronary development is regulated by ATP-dependent SWI/SNF chromatin remodeling component BAF180. Developmental Biology 319, 258-266
107Burrows A.E., Smogorzewska A. and Elledge S.J. (2010) Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proceedings of the National Academy of Sciences of the United States of America 107, 14280-14285
108Bowser R., Giambrone A. and Davies P. (1995) FAC1, a novel gene identified with the monoclonal antibody Alz50, is developmentally regulated in human brain. Developmental Neuroscience 17, 20-37
109Jones M.H., Hamana N. and Shimane M. (2000) Identification and characterization of BPTF, a novel bromodomain transcription factor. Genomics 63, 35-39
110Wysocka J. et al. (2006) A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442, 86-90
111Bochar D.A. et al. (2000) A family of chromatin remodeling factors related to Williams syndrome transcription factor. Proceedings of the National Academy of Sciences of the United States of America 97, 1038-1043
112Collins N. et al. (2002) An ACF1-ISWI chromatin-remodeling complex is required for DNA replication through heterochromatin. Nature Genetics 32, 627-632
113Poot R.A. et al. (2000) HuCHRAC, a human ISWI chromatin remodelling complex contains hACF1 and two novel histone-fold proteins. EMBO Journal 19, 3377-3387
114Strohner R. et al. (2001) NoRC–a novel member of mammalian ISWI-containing chromatin remodeling machines. EMBO Journal 20, 4892-4900
115Ladurner A.G. et al. (2003) Bromodomains mediate an acetyl-histone encoded antisilencing function at heterochromatin boundaries. Molecular Cell 11, 365-376
116Zhou Y. and Grummt I. (2005) The PHD finger/bromodomain of NoRC interacts with acetylated histone H4K16 and is sufficient for rDNA silencing. Current Biology 15, 1434-1438
117Vollmuth F., Blankenfeldt W. and Geyer M. (2009) Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. Journal of Biological Chemistry 284, 36547-36556
118Moriniere J. et al. (2009) Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461, 664-668
119Huang H.D. et al. (2007) Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails. BMC Structural Biology 7, 57
120Umehara T. et al. (2010) Structural implications for K5/K12-di-acetylated histone H4 recognition by the second bromodomain of BRD2. FEBS Letters 584, 3901-3908
121Liu Y. et al. (2008) Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails. Biochemistry 47, 6403-6417
122Sun H. et al. (2007) Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4. Biochemical and Biophysical Research Communications 358, 435-441
123Zeng L. et al. (2008) Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300. Structure 16, 643-652
124Hudson B.P. et al. (2000) Solution structure and acetyl-lysine binding activity of the GCN5 bromodomain. Journal of Molecular Biology 304, 355-370
125Kupitz C., Chandrasekaran R. and Thompson M. (2008) Kinetic analysis of acetylation-dependent Pb1 bromodomain-histone interactions. Biophysical Chemistry 136, 7-12
126Chandrasekaran R. and Thompson M. (2007) Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions. Biochemical and Biophysical Research Communications 355, 661-666
127Dhalluin C. et al. (1999) Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491-496
128Singh M. et al. (2007) Structural ramification for acetyl–lysine recognition by the bromodomain of human BRG1 protein, a central ATPase of the SWI/SNF remodeling complex. Chembiochem 8, 1308-1316
129Tsai W.W. et al. (2010) TRIM24 links a non-canonical histone signature to breast cancer. Nature 468, 927-932
130Wu J.I., Lessard J. and Crabtree G.R. (2009) Understanding the words of chromatin regulation. Cell 136, 200-206
131Gamsjaeger R. et al. (2011) Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Molecular and Cellular Biology 31, 2632-2640
132French C.A. et al. (2001) BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t (15;19). American Journal of Pathology 159, 1987-1992
133French C.A. et al. (2008) BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27, 2237-2242
134French C.A. et al. (2003) BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Research 63, 304-307
135Reynoird N. et al. (2010) Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO Journal 29, 2943-2952
136Filippakopoulos P. et al. (2010) Selective inhibition of BET bromodomains. Nature 468, 1067-1073
137Sobulo O.M. et al. (1997) MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proceedings of the National Academy of Sciences of the United States of America 94, 8732-8737
138Panagopoulos I. et al. (2001) Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Human Molecular Genetics 10, 395-404
139Kasper L.H. et al. (1999) CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Molecular and Cellular Biology 19, 764-776
140Deguchi K. et al. (2003) MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 3, 259-271
141Pasqualucci L. et al. (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471, 189-195
142Bouchal J. et al. (2011) Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer. Prostate 71, 431-437
143Leachman N.T. et al. (2010) ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Development, Growth and Differentiation 52, 747-755
144Khetchoumian K. et al. (2007) Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nature Genetics 39, 1500-1506
145Kikuchi M. et al. (2009) TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochimica Biophysica et Acta 1793, 1828-1836
146Grunwald C. et al. (2006) Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. International Journal of Cancer 118, 2522-2528
147Scanlan M.J. et al. (2000) Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Letters 150, 155-164
148Tong W.G. et al. (2010) Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. Journal of Clinical Oncology 28, 3015-3022
149Crawford N.P.S. et al. (2008) Bromodomain 4 activation predicts breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America 105, 6380-6385
150You J. et al. (2006) Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. Journal of Virology 80, 8909-8919
151Weidner-Glunde M., Ottinger M. and Schulz T.F. (2010) WHAT do viruses BET on? Frontiers in Bioscience 15, 537-549
152Lin A. et al. (2008) The EBNA1 protein of Epstein-Barr virus functionally interacts with Brd4. Journal in Virology 82, 12009-12019
153Nicodeme E. et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123
154Mahdi H. et al. (2009) Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nature Genetics 41, 1319-1324
155Rajendrasozhan S., Yao H. and Rahman I. (2009) Current perspectives on role of chromatin modifications and deacetylases in lung inflammation in COPD. COPD 6, 291-297
156Choi K.C. et al. (2009) Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells. Molecular Cancer Research 7, 2011-2021
157Jung H.J. et al. (2010) Anti-inflammatory activity of n-propyl gallate through Down-regulation of NF-kappaB and JNK pathways. Inflammation. DOI: 10.1007/s10753-010-9241-0
158Deng W.G., Zhu Y. and Wu K.K. (2004) Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 103, 2135-2142
159Cullen S.J., Ponnappan S. and Ponnappan U. (2009) Catalytic activity of the proteasome fine-tunes Brg1-mediated chromatin remodeling to regulate the expression of inflammatory genes. Molecular Immunology 47, 600-605
160Alter M.D. and Hen R. (2008) Putting a KAP on transcription and stress. Neuron 60, 733-735
161Jakobsson J. et al. (2008) KAP1-mediated epigenetic repression in the forebrain modulates behavioral vulnerability to stress. Neuron 60, 818-831
162Bjarkam C.R. et al. (2009) Further immunohistochemical characterization of BRD1 a new susceptibility gene for schizophrenia and bipolar affective disorder. Brain and Structure Function 214, 37-47
163Nyegaard M. et al. (2010) Support of association between BRD1 and both schizophrenia and bipolar affective disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 153B, 582-591
164Loe-Mie Y. et al. (2010) SMARCA2 and other genome-wide supported schizophrenia-associated genes: regulation by REST/NRSF, network organization and primate-specific evolution. Human Molecular Genetics 19, 2841-2857
165Koga M. et al. (2009) Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Human Molecular Genetics 18, 2483-2494
166Rouaux C., Loeffler J.P. and Boutillier A.L. (2004) Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochemical Pharmacology 68, 1157-1164
167Zimmermann N. et al. (2007) Confirmation of EP300 gene mutations as a rare cause of Rubinstein–Taybi syndrome. European Journal of Human Genetics 15, 837-842
168Viosca J. et al. (2010) Syndromic features and mild cognitive impairment in mice with genetic reduction on p300 activity: differential contribution of p300 and CBP to Rubinstein–Taybi syndrome etiology. Neurobiology of Disease 37, 186-194
169Valor L.M. et al. (2011) Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability. Journal of Neuroscience 31, 1652-1663
170Oike Y. et al. (1999) Truncated CBP protein leads to classical Rubinstein–Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Human Molecular Genetics 8, 387-396
171Tanaka Y. et al. (1997) Abnormal skeletal patterning in embryos lacking a single Cbp allele: a partial similarity with Rubinstein–Taybi syndrome. Proceedings of the National Academy of Sciences of the United States of America 94, 10215-10220
172Saura C.A. and Valero J. (2011) The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Reviews in Neurosciences 22, 153-169
173Bartsch O. et al. (2002) Molecular studies in 10 cases of Rubinstein–Taybi syndrome, including a mild variant showing a missense mutation in codon 1175 of CREBBP. Journal of Medical Genetics 39, 496-501
174Petrij F. et al. (1995) Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376, 348-351
175Narayan P. and Dragunow M. (2010) Pharmacology of epigenetics in brain disorders. British Journal of Pharmacology 159, 285-303
176Sachchidanand et al. (2006) Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chemistry and Biology 13, 81-90
177Owen D.J. et al. (2000) The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO Journal 19, 6141-6149
178Chung C.W. et al. (2011) Discovery and characterization of small molecule inhibitors of the BET family bromodomains. Journal of Medicinal Chemistry 54, 3827-3838
179Borah J.C. et al. (2011) A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chemistry and Biology 18, 531-541
180Zeng L. et al. (2005) Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. Journal of the American Chemical Society 127, 2376-2377
Bromodomain structures solved by the Structural Genomics Consortium:http://www.sgc.ox.ac.uk/structures/BRO.html
Chemical probe resource for epigenetic targets:http://www.thesgc.org/chemical_probes/epigenetics/
Disease-annotated chromatin epigenetic resource:http://wodaklab.org/dancer/
The chromatin database:http://www.chromdb.org/
Human Histone Modification Database (HHMD):http://bioinfo.hrbmu.edu.cn/hhmd/
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 43
Total number of PDF views: 352 *
Loading metrics...

Abstract views

Total abstract views: 652 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd November 2017. This data will be updated every 24 hours.